Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.

“…The effect on the glomerular filtration rate is variable and depends on the experimental conditions (Mimran et al, 1979;Hollenberg et al, 1981;McNabb et al, 1986;Navis et al, 1986). Captopril and enalapril cause acute natriuresis (Brunner et al, 1981;Hollenberg et al, 1981;McNabb et al, 1986;Navis et al, 1986) which may be accompanied by potassium retention (Atlas et al, 1979;Navis et al, 1986) or in the case of enalapril by kaliuresis (McNabb et al, 1985(McNabb et al, , 1986. Both drugs have been reported to increase prostaglandin levels (Swartz et al, 1980;Oparil et al, 1983) but there are no data for cilazapril.…”

Section: Introductionmentioning

confidence: 99%

The effects of cilazapril alone and in combination with frusemide in healthy subjects.

Johnston

Passmore

1989

Brit J Clinical Pharma

View full text Add to dashboard Cite

1. In a fourway double‐blind placebo controlled study, the effects of cilazapril, a new angiotensin converting enzyme inhibitor, on renal function and the responses to intravenous frusemide were studied in a group of twelve salt depleted male volunteers. 2. Cilazapril produced an increase in effective renal plasma flow and urinary output of prostaglandin E2 metabolite (PGE2‐M) but no effect on sodium, potassium or water excretion. 3. Pretreatment with cilazapril antagonised the effects of frusemide on glomerular filtration, PGE2‐M and sodium excretion.

show abstract

“…The renin-angiontensin-aldosterone system is of pathogenetic importance in renovascular hypertension, while no such connection has been found in essential hypertension (Beevers et al, 1977). Captopril can reduce blood pressure both in renovascular and essential hypertension (Atkinson & Robertson 1979;Gavras et al, 1978;Bravo & Tarazi, 1979;Atlas et al, 1979). Opinions differ whether its blood-pressure lowering effect in essential hypertension is correlated with plasma renin activity (Laragh, 1978;Case et al, 1978;Karlberg etal., 1981;Bravo & Tarazi, 1979;Gavras etal., 1978;Johnston et al, 1979).…”

Section: Introductionmentioning

confidence: 99%

Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.

Andrén¹,

Karlberg²,

Svensson³

et al. 1982

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Fifty-seven patients with mild or moderate essential hypertension, mean age 50 (range 31-69) were randomised to treatment with either captopril or atenolol. Twenty-six patients in each group completed the study. 2 Captopril (25-50 mg three times daily) and atenolol (50-100 mg once daily) caused a highly significant fall in blood pressure both supine and standing. 3 When hydrochlorothiazide (25-50 mg once daily) was added a further fall in blood pressure was observed in both groups. 4 Captopril as single drug caused no significant change in heart rate, while atenolol significantly reduced heart rate both supine and standing. 5 Two patients were excluded from the captopril group, one because of a reversible loss of taste and the other because of dizziness. Three patients were excluded from the atenolol group, two because of bradyarrhythmias and one because of inadequate blood pressure response. 6 Both captopril and atenolol were found to be effective antihypertensive agents, suitable for the treatment of essential hypertension.

show abstract

Interruption of the renin-angiotensin system in hypertensive patients by captopril induces sustained reduction in aldosterone secretion, potassium retention and natruiresis.

Cited by 180 publications

References 19 publications

Angiotensin I converting enzyme (kininase II) of the brush border of human and swine intestine

Angiotensin I converting enzyme (kininase II) of the brush border of human and swine intestine

The effects of cilazapril alone and in combination with frusemide in healthy subjects.

Captopril and atenolol combined with hydrochlorothiazide in essential hypertension.

Contact Info

Product

Resources

About